Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy with Histone Deacetylase (HDAC) and mTOR
Posted May 14 2012 8:00pm
Description of Invention: Available for licensing is a novel gene signature of thirty-seven drug responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several cancers, including, but not limited to multiple myeloma, lung, breast, and melanoma. Patients identified by this signature would be predicted to benefit from combined HDAC inhibitor/mTOR inhibitor therapy. Additional information is available upon request.
Development of a clinical diagnostic test to identify cancer patients who would benefit most from mTOR and HDAC combination therapy.
Use as a surrogate biomarker related to drug response.
Development of therapeutics targeting several cancers, including multiple myeloma.
Implements a smaller gene set compared to current diagnostic gene signatures.
Provides a basis for the development of a diagnostic for patient stratification or a response measurement related to the combined use of mTOR and HDAC inhibitors for cancer treatment.
Collaborative Research Opportunity: The NCI Center for Cancer Research, Laboratory of Cancer Biology and Genetics, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Methods for Selecting Cancer Patients for HDACi/mTORi Combination Therapy. For collaboration opportunities, please contact John Hewes, Ph.D. at firstname.lastname@example.org .
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220